Literature DB >> 2109581

Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents.

H Nikaido1, W Liu, E Y Rosenberg.   

Abstract

Some enteric bacteria, such as Enterobacter cloacae, can develop high-level resistance to broad-spectrum cephalosporins by overproducing their chromosomally encoded type I beta-lactamases. This is because these agents are hydrolyzed rapidly at pharmacologically relevant, low (0.1 to 1 microM), concentrations, owing to their high affinity for type I enzymes. In contrast, the more recently developed cephalosporins, with quaternary-nitrogen-containing substituents at the 3 position, show increased efficacy against beta-lactamase-overproducing strains and, indeed, have a much lower affinity for type I enzymes. However, the possible contribution of an improved outer membrane permeability in their increased efficacy has not been studied. We found by proteoliposome swelling assays that cefepime, cefpirome, and E-1040 all penetrated the porin channels of Escherichia coli and E. cloacae much more rapidly than did ceftazidime and at least as rapidly as did cefotaxime. Considering that the influx of anionic compounds such as cefotaxime and ceftazidime will be further retarded in intact cells, owing to the Donnan potential, we expect that the newer compounds will penetrate intact cells 2 to 10 times more rapidly than will cefotaxime and ceftazidime. The kinetic parameters of hydrolysis of these agents by E. cloacae beta-lactamase showed that at 0.1 microM, they were hydrolyzed much more slowly than was cefotaxime and at about the same rate as or a lower rate than was ceftazidime. The combination of these two effects explains nearly quantitatively why these newer agents are more effective against some of the beta-lactamase-overproducing gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109581      PMCID: PMC171583          DOI: 10.1128/AAC.34.2.337

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Role of permeability barriers in resistance to beta-lactam antibiotics.

Authors:  H Nikaido
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

2.  Do beta-lactamases 'trap' cephalosporins?

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

3.  Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.

Authors:  C C Sanders
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

4.  Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12.

Authors:  F Yoshimura; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

5.  Porin channels in Escherichia coli: studies with beta-lactams in intact cells.

Authors:  H Nikaido; E Y Rosenberg; J Foulds
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

6.  Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams.

Authors:  H Vu; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes.

Authors:  F Yoshimura; H Nikaido
Journal:  J Bacteriol       Date:  1982-11       Impact factor: 3.490

8.  Chromosomal beta-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins.

Authors:  A H Seeberg; R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

9.  Characterization of beta-lactamase induction in Enterobacter cloacae.

Authors:  T D Gootz; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

10.  Kinetics and significance of the activity of the Sabath and Abrahams' beta-lactamase of Pseudomonas aeruginosa against cefotaxime and cefsulodin.

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  1983-02       Impact factor: 5.790

View more
  58 in total

1.  Contributions of the AmpC beta-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to beta-lactams.

Authors:  A Mazzariol; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Alteration of pore properties of Escherichia coli OmpF induced by mutation of key residues in anti-loop 3 region.

Authors:  Jérôme Bredin; Nathalie Saint; Monique Malléa; Emmanuelle Dé; Gérard Molle; Jean-Marie Pagès; Valérie Simonet
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

3.  Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles.

Authors:  L Martínez-Martínez; M C Conejo; A Pascual; S Hernández-Allés; S Ballesta; E Ramírez De Arellano-Ramos; V J Benedí; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 4.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

5.  Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Authors:  D Yamamura; R Gucalp; P Carlisle; M Cimino; J Roberts; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

6.  Substitutions in the eyelet region disrupt cefepime diffusion through the Escherichia coli OmpF channel.

Authors:  V Simonet; M Malléa; J M Pagès
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

7.  In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis; N J Legakis
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

8.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

Review 9.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 10.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.